Annex 8.1.3: Public-Private Partnerships for Neglected Diseases

Opportunities to address pharmaceutical gaps for neglected diseases

Priority Medicines For Europe and the World"A Public Health Approach to Innovation"

Background Paper for Review

Public-Private Partnerships for Neglected Diseases:

Opportunities to address pharmaceutical gaps for neglected diseases

Annex to Case Studies
Key Personnel for Case Study Organizations

By Elizabeth Ziemba, JD, MPH

26 August 2004

Please send comments to:

Elizabeth Ziemba:

Dr Richard Laing:

Key Personnel for Case Study Organizations

A.Medicines for Malaria Venture (MMV)

The current members of the Board of Directors of MMV are:[1]

Chair, Board of Directors:

The Chair of the MMV Board is Dame Bridget Ogilvie,a former head of the Wellcome Trust. Following adistinguished career in pharmaceutical research, Dame Bridgetcurrently serves on the faculty of University College London. She was elected as aFellow of the Royal Society in 2003.

The Board of Directors is composed of the following individuals:

Dame Bridget Ogilvie FRS,UniversityCollegeLondon, United Kingdom(Chair of MMV Board)

Dr Enriqueta Bond, President, Burroughs Wellcome Fund, USA

Dr Jack Chow, Assistant Director-General, HIV/AIDS, TB and Malaria, World Health Organization, Switzerland

Dr Chris Hentschel, Chief Executive Officer, Medicines for Malaria Venture (MMV), Switzerland

Prof. Trevor Jones, Director General, The Association of the British Pharmaceutical Industry (ABPI), United Kingdom

Dr R. A. Mashelkar, Director General,Council of Scientific and Industrial Research (CSIR), India

Dr Pascoal M. Mocumbi,High Representative of the European and Developing Countries Clinical Trials Partnership (EDCTP); former Prime Minister of Mozambique

Prof. Francis Nkrumah, Director, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana

Prof. Leon Rosenberg, Department of Molecular Biology, Princeton University, USA.

Expert Scientific Advisory Committee (ESAC):

The members of ESAC are:[2]

Chair:

DrWin Gutteridge, former Chief, Product R&D, Special Programme for

Research and Training in Tropical Diseases (TDR), World Health Organization, Switzerland

Members:

Dr David Floyd,former Vice-President, Discovery Chemistry, Bristol-Myers Squibb; currently Head of Focus Consulting

Dr Alan Hudson,Chemist, former Head of Cancer Research, Wellcome plc (UK) with additional expertise in parasitology and malaria chemotherapy

Dr David Roos, Professor of Biology and Director, University of Pennsylvania Genomics Institute. Expertise in the cell biology of apicomplexan parasites and joint coordinator of the Plasmodium genome database, USA

Dr Dennis Schmatz, Biologist with expertise in parasitology, including malaria. Executive Director, Human and Animal Infectious Disease Research, Merck Research Laboratories, USA

Professor Robert (Bob) William Snow, Head, Malaria Public Health Group, KEMRI/Wellcome Trust Programme, Nairobi, Kenya

Dr Thomas E. Wellems, Biologist with expertise in cell and molecular biology of malaria and mechanisms of drug resistance. National Institute of Allergy and Infectious Diseases/National Institutes of Health, USA

Dr Kitima Yuthavong, medical doctor; formerly with Aventis.

Management Team:[3]

The Chief Executive Officer of MMV is Dr. Christopher Hentschel. A bio-pharmaceutical executive with more than 20 years' international R&D and technology transfer management experience in both private and public sectors, Dr. Hentschel serves as a non-executive director of a number of biotechnology companies, as an advisor of a European Venture Capital Fund and as a Senior Research Fellow of the WhartonBusinessSchool's Emerging Technology Program.

Other individuals on the management team and staff include: Dr J Carl Craft, ChiefScientific Officer; Mr. Peter Potter-Lesage, Chief Financial Officer; Dr P VVenugopal, Director, International Operations; Diana Cotran, Human Resources andAdministration Manager; Dr Solomon Nwaka, Scientific Officer; Dr Lise Riopel, Scientific Officer; Dr David Ubben, Scientific Officer; Marion Hutt, Science Team Administrator; Anna Wang, Communication and Advocacy Officer; and Erin Kimaoui, Assistant to the CEO, Website/MMVnews Coordinator.[4]

B.Drugs for Neglected Diseases (DNDi)

The current Board of Director members are:[5]

Chairman:

Yves Champey, Chairman of the Board for a term of two years.

Members:

BRUN Reto, Director, Swiss Tropical Institute

FERREIRA Jose Roberto, Director International Cooperation, Fiocruz

(Secretary)

KANT Lalit, Senior Deputy Director General, ICMR

KOECH Davy, Director, KEMRI

KOURILSKY Philippe, Director General, Institut Pasteur

MAHIN Bruce, financial Director, MSF France (Treasurer)

MERICAN Dato (Dr) Ismail, Deputy Director General of Health, Malaysian MoH

ROSTRUP Morten, President, MSF International

Carlos Morel (TDR) will be Permanent Observer

Scientific Advisory Committee (SAC):

The members of the Scientific Advisory Committee are:

Chair
WIRTH Dyann / Professor, HarvardSchool of Public Health, Chair of the TDR Strategic Research Committee
Members representing Founding Partner institutions
BHATT Kirana / (KEMRI) Associate Professor, Department of Medicine, University of Nairobi
BOECHAT Nubia / (FIOCRUZ) Director, Far Manguinhos
BOELAERT Marleene / (MSF), Scientist at the Antwerp Leopold Tropical Diseases Institute
BOST Pierre-Etienne / (Institut Pasteur) Director, Medicinal Chemistry Unit, CNRS
FAIRLAMB H. Alan / (TDR) Professor and Head, Division of Biological Chemistry & Molecular Microbiology, University of Dundee
NAVARATNAM
Visweswaran / (Malaysian Ministry of Health) Professor, Clinical Pharmacology, University Sains
SETH Shiv Dayal / (ICMR) Chair, Clinical Pharmacology Department, ICMR
Members from external institutions
FOLB Peter / Professor of Pharmacology, Director WHO Collaborating Centre for Drug Policy, University of Cap Town, South Africa
GUPTA Chhittar Mal / Director, Central Drug Research Institute, Lucknow, India
HERRLING Paul / Head, Corporate Research, Novartis, Basel, Switzerland
SHAPIRO Bennett / Executive VP External Research and Worldwide Licensing, Merck, USA
URBINA Julio / Director, Biological Chemistry Laboratory, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela
YAMADA Haruki / Vice President Research, The Kitasato Institute, Tokyo
YUTHAVONG Yongyuth / Chair of Pharmacology, Director Thailand Graduate institute of Science and Technology, Bangkok, Thailand

Extracted from the DNDi website,

Accessed 5 March 2004.

C.Global Alliance for Tuberculosis Research (TB Alliance)

The members of the Board of Directors of the Global Alliance for Tuberculosis Research are:[6]

Dr. Gail Cassell

Vice President, Scientific Affairs, Eli Lilly and Company

Dr. Gijs Elzinga, Chair

Deputy Director-General, Netherlands' National Institute of Public Health and the Environment

Dr. Maria C. Freire

Chief Executive Officer, Global Alliance for TB Drug Development

Dr. Paul Herrling

Head of Corporate Research, Novartis International AG

Mr. Charles Kaye, Treasurer

Co-President, Warburg Pincus

Mr. Seán Lance

Chairman of the Board, Chiron Corporation

Dr. John La Montagne

Deputy Director, U.S. National Institute of Allergy and Infectious Diseases/National Institutes of Health

Dr. Carlos Morel, Vice Chair

Director, Special Programme for Research and Training in Tropical Diseases/World Health Organization

Dr. Ariel Pablos-Méndez, Secretary

Acting Director, Health Equity, Rockefeller Foundation

Dr. Lee Reichman

President, TB Alliance Stakeholders' Association

Executive Director, New JerseyMedicalSchoolNationalTuberclosisCenter

Sir David Weatherall

Founding Director Emeritus, Weatherall Institute of Molecular Medicine, University of Oxford

Members of the Stakeholders Association[7]

The following institutions formally pledged to accelerate the development of TB drugs. They advise, guide, and support the efforts of the Global Alliance for TB Drug Development:

  • American Lung Association (ALA)
  • American Society for Tuberculosis Education and Research (ASTER)
  • American Thoracic Society (ATS)
  • Association of the British Pharmaceutical Industry (ABPI)
  • Bill and Melinda Gates Foundation
  • Centers for Disease Control and Prevention (CDC)
  • European Commission
  • Global Forum for Health Research
  • International Union Against Tuberculosis and Lung Disease (IUATLD)
  • Lupin Laboratories
  • Médecins Sans Frontières-Doctors without Borders (MSF)
  • Medical Research Council of South Africa (MRC)
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH)
  • National Institute of Pharmaceutical Education and Research, India (NIPER)
  • New JerseyMedicalSchoolNationalTuberculosisCenter
  • Novartis India, Ltd
  • Partners in Health
  • Philippines Coalition Against Tuberculosis (PHILCAT)
  • Research Institute of the Japan Anti-TB Association (JATA)
  • Research Triangle Institute (RTI)
  • Rockefeller Foundation
  • Royal Netherlands Tuberculosis Association (KNCV)
  • Sequella Global Tuberculosis Foundation
  • Stop TB
  • U.K. Department for International Development (DFID)
  • U.N. Programme for Research and Training in Tropical Diseases (TDR)
  • U.S. Agency for International Development (USAID)
  • Wellcome Trust
  • World Bank
  • World Health Organization

2004 Scientific Advisory Committee:[8]

Dr. Clifton Barry, III

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dr. Ken Duncan

GlaxoSmithKline

Dr. Bernard Fourie, Secretary

Medical Research Council of South Africa

Dr. Maria C. Freire

Global Alliance for TB Drug Development

Dr. Jacques Grosset

The JohnsHopkinsUniversity

Dr. Yoshiaki Kiso

KyotoPharmaceuticalUniversity

Dr. Barbara Laughon, Chair

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dr. Christopher Lipinski

Pfizer Inc.

Dr. Denis Mitchison

St. George’sHospitalMedicalSchool

Dr. Richard O’Brien

Foundation for Innovative New Diagnostics

Dr. Ramesh Panchagnula

Indian National Institute of Pharmaceutical Education and Research

Dr. Philippe Prokocimer

Johnson & Johnson

Dr. Christine Sizemore

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dr. C. Kendall Stover

Pfizer Inc.

Senior Management, Staff and Consultants of TB Alliance:[9]

Maria C. Freire, Ph.D.
Chief Executive Officer

Mel Spigelman, M.D.
Director, Research and Development

Joelle Tanguy
Director, Advocacy & Public Affairs

Bradley Jensen
Director, Finance & Administration

Serdar Elmali

Information Technology and Networking Consultant

Beatrice M. Evangelista

Officer, Public Affairs

Ann Ginsberg, M.D., Ph.D.

Head of Clinical Development

Marilyn Hartig, Ph.D.

Consultant, Industry Relations

Dean Haubrich, Ph.D.

Head of Project Management

Heather Ignatius

Policy Fellow, Advocacy & Public Affairs

Zhenkun Ma, Ph.D.

Head of Research

Gwynne Oosterbaan

Assistant Director, Public Affairs

Doris Rouse, Ph.D.

Portfolio Project Manager

Muntaha Sabah Lazim

Administrative Manager - Europe

Gerald J. Siuta, Ph.D.

Consultant, Business Development

Karen Wright

Senior Advisor

D.International AIDS Vaccine Initiative (IAVI)

Board of Directors

The members of the Board of Directors of IAVI are:[10]

. Seth Berkley, MD, President and Chief

Executive Officer, IAVI

. Awa Marie Coll-Seck, Executive Secretary, Roll

Back Malaria Partnership, WHO, Geneva;

Former Director, Policy, Strategy and Research,

UNAIDS

. Ciro de Quadros, MD, MPH, Director,

International Programs, Sabin Vaccine Institute;

Former Director, Vaccines and Immunization,

Pan American Health Organization

. John D. Evans, Treasurer, Chairman & CEO,

Evans Telecommunications Co. and The John D.

Evans Foundation

. Michel Greco, Former Deputy CEO, Aventis

. Geeta Rao Gupta, PhD, President,

InternationalCenter for Research on Women

. Ian Gust, MD, Ex-officio, Chair, IAVI Scientific

Advisory Committee, Department of

Microbiology & Immunology, The University of

Melbourne; Former Director of R&D, CSL Ltd.

. Glenys Kinnock, Member of European

Parliament, Wales

. Chrispus Kiyonga, MD, Minister without

Portfolio, Uganda; Former Chair of the Global

Fund to Fight AIDS, Tuberculosis, and Malaria;

Former Minister of Health, Uganda

. Paul Klingenstein, President of Aberdare

Ventures

. Geoffrey Lamb, Board Chair, Vice President

for Concessional Finance and Global

Partnerships, The World Bank

. Malegapuru William Makgoba, MBShB, DPhil,

FRCP, FRSSAf, MASSAf, Vice Chancellor,

University of Natal; Former President, Medical

Research Council, South Africa

. Peter Piot, MD, PhD, Ex-officio, Executive

Director, Joint United Nations Programme on

HIV/AIDS

. Philip Russell, MD, Secretary, Special Advisor,

Vaccine Development and Production, US

Department of Health and Human Services;

Professor, International Health, Johns Hopkins

University

. Kapil Sibal, JD, Member of Parliament, India

. Lee Smith, Founding Chairperson, Former

President, Levi Strauss International; Former

Chairperson, US National Leadership Coalition

on AIDS

. Sir Richard Sykes, DSc, FRS, Rector, Imperial

College of Science, Technology, and Medicine;

Former Chairperson and Chief Executive

Officer, GlaxoSmithKline plc

MEMBERS EMERITUS

. Michèle Barzach, MD, Former Minister of

Health, France

. Gordon Douglas, MD, Consultant, Vaccines,

Infectious Disease and Global Health, Former

President, Merck Vaccines, Merck and Co., Inc.

. Richard Feachem, PhD, DSc (Med), Executive

Director, Global Fund to Fight AIDS,

Tuberculosis, and Malaria; Founding Director,

Institute for Global Health, University of

California

. Jaap Goudsmit, MD, PhD, Executive Vice

President, Research & Development, Chief

Scientific Officer, CrucellNV; Co-Founder,

European Vaccine Effort Against HIV/AIDS

. Jacques-François Martin, President, Vaccine

Fund; Former Chief Executive Officer, Pasteur-

Mérieux

. Shudo Yamazaki, MD, PhD, Director-General

Emeritus, National Institute of Infectious

Diseases, Japan

The members of the Scientific Advisors Committee for IAVI are:x

Dennis Burton, PhD, Professor, Immunology,

Scripps Research Institute

John G. Curd, MD, President & Chief Medical

Officer, Novacea, Inc.

Michel De Wilde, PhD, Executive Vice

President, Research and Development, Aventis

Pasteur SA

Ronald C. Desrosiers, PhD, Professor,

Microbiology & Molecular Genetics, Harvard

MedicalSchool; Director, New England Primate

ResearchCenter

Ian Gust, MD, Chair, Professor, Microbiology

and Immunology, University of Melbourne;

Former Director of R&D, CSL Ltd.

Philip Johnson, MD, President, Columbus

Children’s Research Institute, Columbus

Children’s Hospital

Liming Lee, MD, MPH, President, Chinese

Academy of Preventive Medicine

Norman Letvin, MD, Chief, Viral Pathogenesis,

BethIsraelDeaconessMedicalCenter;

Professor, Medicine, HarvardMedicalSchool

Andrew McMichael, MD, PhD, Director,

Weatherall Institute of Molecular Medicine,

University of Oxford

Rosemary Mubanga Musonda, Acting Director

General, Zambia National AIDS Council

Neal Nathanson, MD, Vice Provost for

Research, University of Pennsylvania;

Former Director, Office of AIDS Research, US

National Institutes of Health

Helen Rees, MBBCh, Executive Director,

Reproductive Health Research Unit, Chris Hani

BaragwanathHospital

Jerald C. Sadoff, MD, President & CEO, AERAS

Global Tuberculosis Foundation; Former Clinical

Director for Vaccine Development, Merck and

Co. Inc.

Mauro Schechter, MD, PhD, Professor,

Infectious Diseases, Federal University of Rio de

Janeiro

Hans Wigzell, MD, DSc, President, Karolinska

Institute

Vaccine Research & Design Subcommittee

. Rafi Ahmed, EmoryUniversity

. Dennis Burton, Scripps Research Institute

. Ronald Desrosiers, HarvardMedicalSchool

. Kim J. Hasenkrug, NIAID, NIH

. Shiu Lok Hu, University of Washington

. Philip Johnson, Chair, Columbus Children’sHospital

. Kelly MacDonald, University of Toronto

. Doug Nixon, Gladstone Institute of Virology &Immunology .Quentin Sattentau, University of Oxford

. Bruce Walker, Massachusetts GeneralHospital

. David Watkins, University of WisconsinMedicalSchool

. Lindsey Whitton, Scripps Research Institute

Project Management Subcommittee

. Kenneth R. Brown, GordonCollege

. John Curd, Novacea

. Marie-Paule Kieny, Chair, WHO/IVR

. Jack Melling, Consultant

. John Petricciani, CancerVax Corp.

. Stanley Plotkin, Aventis Pasteur

. Jerry Sadoff, AERAS Global TuberculosisFoundation

. Vijay Samant, Vical Inc.

. Michel De Wilde, Aventis Pasteur SA

Clinical Trials Subcommitte

. Donald S. Burke, JohnsHopkinsUniversity

. Beryl Koblin, New YorkBloodCenter

. Ira Longini, EmoryUniv.School of Public Health

. Helen Rees, Chair, Univ. of the Witwatersrand

. Wasima Rida, Statistics Collaborative, Inc.

. Mauro Schechter, Federal University of Rio deJaneiro

. Haynes W. Sheppard, California Department ofHealth Services

. Hilton Whittle, MRC Laboratories

. James Whitworth, The LondonSchool ofHygiene & Tropical Medicine

The members of the Policy Advisors Committee for IAVI are:x

. David Kihumuro Apuuli, MD

Director-General, Uganda AIDS Commission

. Amie Batson, MPPM

Senior Health Specialist, World Bank and Cochair

of Global Alliance for Vaccines &

Immunization Financing Task Force

. Donald S. Burke, MD

Director, Center for Immunization Research,

Department of International Health, Johns

HopkinsUniversitySchool of Hygiene &

Public Health

. Chris Collins (Observer)

Executive Director, AIDS Vaccine Advocacy

Coalition

. Ciro de Quadros, MD, MPH

Member, IAVI Board of Directors;

Director of International Programs, Albert B.

Sabin Vaccine Institute

. R. Gordon Douglas Jr., MD

Member Emeritus, IAVI Board of Directors;

Director, Strategic Planning, Dale & Betty

Bumpers Vaccine Research Center, US

National Institutes of Health; Former

President, Merck Vaccines, Merck and Co.

Inc.

. Christopher J. Elias, MD, MPH

President, Program for Appropriate

Technology in Health

. Lieve Fransen, MD, PhD

Head, Social & Human Development Policy &

Programming, Directorate-General

Development, European Commission

. David L. Heymann, MD (Observer)

Executive Director, Communicable Diseases,

World Health Organization

. Purnima Mane, MA, MPhil, PhD

Chief Fund Portfolio Director & Director for

Asia, The Global Fund to Fight AIDS,

Tuberculosis & Malaria

. Jean-Marie Okwo-Bele, MD, MPH

Senior Advisor & Team Leader, Immunization

Plus, UNICEF

. Bernard Peçoul, MD, MPH

Executive Director, Drugs for Neglected

Diseases Initiative (DNDi)

. Seung-il Shin, PhD

Senior Advisor, International Development,

VaxGen Inc.

. Jean Stéphenne

President & General Manager,

GlaxoSmithKline Biologicals

. Joseph Stiglitz, PhD

Professor of Economics & Finance, Columbia

University

. Mark Wainberg, PhD

Director, McGillUniversity AIDS Centre

The members of IAVI’s management and staff are:[11]

Executive Office

Seth F. Berkley, M.D.
President and Chief Executive Officer / 212 847 1100

A specialist in infectious disease epidemiology and international health, Dr. Berkley is former Associate Director, Health Sciences Division, at The Rockefeller Foundation. He has also worked for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention, the Massachusetts Department of Public Health and for the Carter Center, where he was assigned in the late 1980s as the epidemiologist at the Ministry of Health in Uganda and was involved in the country’s first study of HIV prevalence and developing its National AIDS Control programs. The author of more than 85 publications, he has written extensively on infectious disease and international health including participating as a core team member in writing the World Bank’s 1993 World Development Report on Health. Dr. Berkley is Adjunct Professor of Public Health at ColumbiaUniversity and Adjunct Professor of Medicine at BrownUniversity. He received his medical degree from BrownUniversity and trained in internal medicine at HarvardUniversity.